| Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies P Tarantino, R Carmagnani Pestana, C Corti, S Modi, A Bardia, ... CA: a cancer journal for clinicians 72 (2), 165-182, 2022 | 289 | 2022 |
| IL-6–mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages P Kothari, R Pestana, R Mesraoua, R Elchaki, KM Khan, AJ Dannenberg, ... The Journal of Immunology 192 (1), 349-357, 2014 | 158 | 2014 |
| Hepatocellular carcinoma immunotherapy RC Sperandio, RC Pestana, BV Miyamura, AO Kaseb Annual review of medicine 73 (1), 267-278, 2022 | 141 | 2022 |
| Histology-agnostic drug development—considering issues beyond the tissue RC Pestana, S Sen, BP Hobbs, DS Hong Nature Reviews Clinical Oncology 17 (9), 555-568, 2020 | 85 | 2020 |
| Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA AO Kaseb, NS Sánchez, S Sen, RK Kelley, B Tan, AG Bocobo, KH Lim, ... Clinical Cancer Research 25 (20), 6107-6118, 2019 | 80 | 2019 |
| Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma AO Kaseb, L Vence, J Blando, SS Yadav, N Ikoma, RC Pestana, ... Cancer immunology research 7 (9), 1390-1395, 2019 | 69 | 2019 |
| Moving beyond 3+ 3: the future of clinical trial design R Kurzrock, CC Lin, TC Wu, BP Hobbs, RC Pestana, DS Hong American Society of Clinical Oncology Educational Book 41, e133-e144, 2021 | 66 | 2021 |
| Prognostic factors in patients with metastatic breast cancer with bone‐only metastases A Parkes, CL Warneke, K Clifton, A Al‐Awadhi, O Oke, RC Pestana, ... The oncologist 23 (11), 1282-1288, 2018 | 60 | 2018 |
| Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials S Sen, RC Pestana, K Hess, GM Viola, V Subbiah Annals of Oncology 29 (12), 2396-2398, 2018 | 57 | 2018 |
| Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC A Kaseb, DG Duda, HST Cao, YI Abugabal, LM Vence, A Rashid, ... Annals of Oncology 30, v880, 2019 | 56 | 2019 |
| Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma RC Pestana, M Becnel, ML Rubin, DK Torman, J Crespo, J Phan, ... Oral Oncology 101, 104523, 2020 | 53 | 2020 |
| Origin and role of hepatic myofibroblasts in hepatocellular carcinoma BG Yavuz, RC Pestana, YI Abugabal, S Krishnan, J Chen, MM Hassan, ... Oncotarget 11 (13), 1186, 2020 | 46 | 2020 |
| Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC A Qayyum, KP Hwang, J Stafford, A Verma, DM Maru, S Sandesh, J Sun, ... Journal for immunotherapy of cancer 7, 1-6, 2019 | 44 | 2019 |
| Precision oncology in sarcomas: divide and conquer R Carmagnani Pestana, R Groisberg, J Roszik, V Subbiah JCO Precision Oncology 3, 1-16, 2019 | 32 | 2019 |
| Systemic options for malignant peripheral nerve sheath tumors A Hassan, RC Pestana, A Parkes Current treatment options in oncology 22 (4), 33, 2021 | 29 | 2021 |
| Unique aberrations in intimal sarcoma identified by next-generation sequencing as potential therapy targets J Roszik, A Khan, AP Conley, JA Livingston, R Groisberg, V Ravi, ... Cancers 11 (9), 1283, 2019 | 26 | 2019 |
| Basket trials: review of current practice and innovations for future trials BP Hobbs, RC Pestana, EC Zabor, AM Kaizer, DS Hong Journal of Clinical Oncology 40 (30), 3520-3528, 2022 | 22 | 2022 |
| Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma RC Pestana, MM Hassan, R Abdel-Wahab, YI Abugabal, LM Girard, D Li, ... Oncotarget 9 (102), 37721, 2018 | 21 | 2018 |
| Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil RC Pestana, EI Baracat, PCB Massarollo, LA Pereira, LA Szutan Transplantation proceedings 45 (6), 2111-2114, 2013 | 21 | 2013 |
| Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives M Zugman, G Botrus, RC Pestana, PLS Uson Junior Frontiers in Oncology 12, 860453, 2022 | 18 | 2022 |
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer CenterBestätigte E-Mail-Adresse bei mdanderson.org